These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26227824)

  • 1. Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.
    Thumma SC; Jacobson BA; Patel MR; Konicek BW; Franklin MJ; Jay-Dixon J; Sadiq A; De A; Graff JR; Kratzke RA
    Cancer Gene Ther; 2015 Aug; 22(8):396-401. PubMed ID: 26227824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
    Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
    PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.
    Liu F; Wang X; Li J; Gu K; Lv L; Zhang S; Che D; Cao J; Jin S; Yu Y
    Cell Prolif; 2015 Oct; 48(5):582-92. PubMed ID: 26250586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.
    Liu S; Wang W; Ning Y; Zheng H; Zhan Y; Wang H; Yang Y; Luo J; Wen Q; Zang H; Peng J; Ma J; Fan S
    Cell Death Dis; 2022 Feb; 13(2):129. PubMed ID: 35136028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
    Li Y; Fan S; Koo J; Yue P; Chen ZG; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Cancer Biol Ther; 2012 Mar; 13(5):272-80. PubMed ID: 22236867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.
    Li S; Jia Y; Jacobson B; McCauley J; Kratzke R; Bitterman PB; Wagner CR
    Mol Pharm; 2013 Feb; 10(2):523-31. PubMed ID: 23289910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI.
    Attar-Schneider O; Drucker L; Gottfried M
    Lab Invest; 2016 Sep; 96(9):1004-15. PubMed ID: 27501049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.
    Jacobson BA; Ahmad Z; Chen S; Waldusky G; Dillenburg M; Stoian E; Cambron DA; Patel AJ; Patel MR; Wagner CR; Kratzke RA
    Invest New Drugs; 2021 Jun; 39(3):636-643. PubMed ID: 33230623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells.
    Goldson TM; Vielhauer G; Staub E; Miller S; Shim H; Hagedorn CH
    Mol Carcinog; 2007 Jan; 46(1):71-84. PubMed ID: 17091471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
    Duffy AG; Makarova-Rusher OV; Ulahannan SV; Rahma OE; Fioravanti S; Walker M; Abdullah S; Raffeld M; Anderson V; Abi-Jaoudeh N; Levy E; Wood BJ; Lee S; Tomita Y; Trepel JB; Steinberg SM; Revenko AS; MacLeod AR; Peer CJ; Figg WD; Greten TF
    Int J Cancer; 2016 Oct; 139(7):1648-57. PubMed ID: 27194579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
    Graff JR; Konicek BW; Vincent TM; Lynch RL; Monteith D; Weir SN; Schwier P; Capen A; Goode RL; Dowless MS; Chen Y; Zhang H; Sissons S; Cox K; McNulty AM; Parsons SH; Wang T; Sams L; Geeganage S; Douglass LE; Neubauer BL; Dean NM; Blanchard K; Shou J; Stancato LF; Carter JH; Marcusson EG
    J Clin Invest; 2007 Sep; 117(9):2638-48. PubMed ID: 17786246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting translation: eIF4E as an emerging anticancer drug target.
    Lu C; Makala L; Wu D; Cai Y
    Expert Rev Mol Med; 2016 Jan; 18():e2. PubMed ID: 26775675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.
    Graff JR; Konicek BW; Lynch RL; Dumstorf CA; Dowless MS; McNulty AM; Parsons SH; Brail LH; Colligan BM; Koop JW; Hurst BM; Deddens JA; Neubauer BL; Stancato LF; Carter HW; Douglass LE; Carter JH
    Cancer Res; 2009 May; 69(9):3866-73. PubMed ID: 19383915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer.
    Wang D; Ma J; Ji X; Xu F; Wei Y
    Oncol Rep; 2017 Jan; 37(1):608-616. PubMed ID: 27840955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
    Pang W; Tian X; Bai F; Han R; Wang J; Shen H; Zhang X; Liu Y; Yan X; Jiang F; Xing L
    Mol Cancer; 2014 Oct; 13():240. PubMed ID: 25342548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
    De A; Jacobson BA; Peterson MS; Jay-Dixon J; Kratzke MG; Sadiq AA; Patel MR; Kratzke RA
    Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer.
    Khoury T; Alrawi S; Ramnath N; Li Q; Grimm M; Black J; Tan D
    Clin Lung Cancer; 2009 Jan; 10(1):58-66. PubMed ID: 19289374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
    Xu M; Tao Z; Wang S; Jiang Y; Qu M
    Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.